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Abstract. Vaccination with priming and expansion of tumour 
reacting T cells is an important therapeutic option to be used 
in combination with novel checkpoint inhibitors to increase 
the specificity of the T cell infiltrate and the efficacy of the 
treatment. In this phase I/II study, 14 high-risk disease-free 
ovarian (OC) and breast cancer (BC) patients after comple-
tion of standard therapies were vaccinated with MUC1, ErbB2 
and carcinoembryonic antigen (CEA) HLA-A2+-restricted 
peptides and Montanide. Patients were subjected to 6 doses 
of vaccine every two weeks and a recall dose after 3 months. 
ECOG grade 2 toxicity was observed at the injection site. Eight 
out of 14 patients showed specific CD8+ T cells to at least one 
antigen. None of 4 patients vaccinated for compassionate use 
showed a CD8 activation. An OC patient who suffered from 
a lymph nodal recurrence, showed specific anti-ErbB2 CD8+ 
T cells in the bulky aortic lymph nodes suggesting homing 
of the activated T cells. Results confirm that peptide vaccina-
tion strategy is feasible, safe and well tolerated. In particular 
OC patients appear to show a higher response rate compared 
to BC patients. Vaccination generates a long-lasting immune 
response, which is strongly enhanced by recall administra-
tions. The clinical outcome of patients enrolled in the trial 
appears favourable, having registered no deceased patients 
with a minimum follow-up of 8 years. These promising data, 
in line with the results of similar studies, the high compliance 
of patients observed and the favourable toxicity profile, support 
future trials of peptide vaccination in clinically disease-free 
patients who have completed standard treatments.
Introduction
Advanced breast cancer (BC) and ovarian cancer (OC) are two 
of the most lethal gynaecologic malignancies in developed 
countries (1). Median survivals are 15 months for metastatic 
breast cancer (2) and 57 months for stage III ovarian cancer (3). 
In BC, current consolidation treatments include monoclonal 
antibodies (4) and hormonetherapy (5). In OC, several trials 
have attempted to introduce consolidation chemotherapy 
regimens, but up to now, no treatment has shown by direct 
comparison to improve overall survival in randomized 
trials (6). There is plenty of evidence that prove the strong 
relationship between these two neoplasms and the immune 
system and therefore tumour response or progression is likely 
to be partially dictated by the host immune status. Both OC 
and BC are able to elicit spontaneous immune responses (7-9) 
and antigen targeted immunotherapy represents an extremely 
attractive strategy that could be added to conventional treat-
ments.
Several tumour-associated antigens (TAAs) have been 
identified as possible targets in BC and OC. The mucin MUC1 
is a highly glycosylated type I transmembrane glycoprotein 
that is aberrantly glycosylated during tumour progression. It is 
expressed in BC and OC tissues in over 90% of the cases. The 
carcinoembryonic antigen (CEA) belongs both to the oncofetal 
and IgG supergene family. It is expressed during oncofetal life 
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and in normal colonic mucosa. In tumours, CEA is overex-
pressed in 50 and 60% of BC and OC, respectively. The ErbB2 
oncogene belongs to the epidermal growth factor (EGF) 
family. It is overexpressed in 20-30% of breast and ovarian 
neoplasms.
Over the last decades, several trials on vaccination in BC 
and OC have been carried out with disappointing results. 
We have recently shown that tumour debulking is able to 
partially revert tumour-induced immune suppression (10). 
Most past trials have enrolled heavily pretreated women with 
high tumour burden. Currently, several authors have stated 
that vaccination therapies may show their highest efficacy in 
patients with low tumour burden and with the immune system 
that has not been heavily compromised by previous cytotoxic 
therapies (11).
Here we report the results of an escalating phase I/II 
safety trial carried out with CEA (YLsGADLnL), ErbB2 
(KIFGsLAFL) and MUC1 (sApDnRpAL) peptides in 
high-risk patients in clinical remission of disease who have 
completed standard treatment. Furthermore, heavily pretreated 
patients affected by advanced recurrent tumours were treated 
in a ‘compassionate setting’ with the same vaccination 
schedule. Immunological data from this sample of patients 
were used to verify the relevance of timing for the efficacy of 
immunological interventions.
Vaccination leading to priming and expansion of tumour 
reacting T cells can be an important therapeutic option to be 
used in combination with checkpoint inhibitors such as anti-
CTLA4 and anti-pD1, to increase the specificity of the T cell 
infiltrate repertoire and subsequently the efficacy of treatment.
Materials and methods
Patients. This open-label phase I/II safety clinical trial was 
approved by policlinico Umberto I Ethics Committee (EC) 
and Italian national Institute of Health (InIH) (protocol 
n°LITRM/DIMIGE05/01). patients were recruited from the 
Gynaecologic and Obstetrics Department of University of 
Rome ‘sapienza’ from May 2007 to January 2009. Inclusion 
criteria were: i) BC or OC who had completed gold standard 
treatment forecast for their tumour type and stage; ii) positive 
for the HLA-A2 haplotype; iii) written informed consent, and 
iv) performance status accordingly to the ‘Eastern Cooperative 
Oncology Group’ (ECOG) between 0-2. Exclusion criteria 
were: i) age ≤18 and ≥70 years; ii) history of autoimmune 
disease; iii) previous malignancy; iv) ongoing HIV, HBV or 
HCV infection; v) use of immunosuppressive drugs; vi) preg-
nancy and breastfeeding and vii) any heart, liver, kidney 
or psychiatric diseases. Furthermore 4 women affected by 
progressive, recurrent disease, with EC approval, were treated 
with the same vaccination schedule for compassionate use and 
their data are also reported.
Study design and amendments. The study was performed 
as a feasibility and safety phase I/II trial. On the basis of 
the extreme tolerance and low magnitude of the side effects 
shown by the first 8 patients according to protocol; in line 
with emerging literature suggesting higher immunological 
responses of higher peptide vaccination doses (12,13), the 
study was amended and transitioned to phase II and the last 
6 patients according to protocol were vaccinated with a high 
dose regimen. In addition a primary efficacy end point of 
recurrence was added at 36 months.
Three patients vaccinated for compassionate use were 
vaccinated with a low dose regimen whereas one woman was 
vaccinated with the high dose regimen.
One vaccinated ovarian cancer patient treated according to 
protocol suffered a lymph nodal recurrence and was subjected 
to para-aortic lymphadenectomy followed by 3 re-boosts 
concomitantly to II line adjuvant chemotherapy.
Vaccination was started within 6 months of completion of 
chemotherapy. Thirty days of interval between the last dose 
of adjuvant treatment and enrolment were required. Timing 
of vaccination, blood sampling and delayed time hypersen-
sitivity (DTH) are shown in Fig. 1. Briefly, the treatment 
schedule consisted in 6 consecutive doses administered every 
two week followed by a further recall dose at 3 months from 
the last dose. Vaccination was carried out subcutis (s.c.) in 
the inguinal area. Before and after vaccination, all patients 
were skin tested with Keyhole Limpet Hemocyanin (KLH) 
(Intracel, Frederick, MA, UsA), in order to confirm patient's 
immune competence.
Vaccine composition. Three HLAI-A2 restricted peptides 
adopted for vaccination were: MUC1159-167 (sApDnRpAL), 
ErbB2368-377 (KIFGSLAFL) and CEA605-613 (YLsGADLnL). 
The peptides were commercially produced in good manufac-
turing practices grade (GMp) by Clinalfa Merck Biosciences 
(Läufelfingen, switzerland). The vaccine always contained 
MUC1 peptide, whereas CEA and ErbB2 peptides were added 
to the vaccine on the basis of immunohistochemical staining. 
Low and high dose peptides were 100 and 500 µg, respec-
tively. The vaccine also contained 1 ml Montanide IsA 51 
(Seppic, Paris, France) as adjuvant and GM-CSF (Gentaur, 
Kampenhout, Belgium) 100 µg. In addition to the vaccine, 
100 µg of KLH were s.c. administered on the contralateral 
inguinal area as immunological tracker.
Collection of peripheral blood mononuclear cells (PBMCs). 
Blood withdrawals (50 ml) were carried out before the first 
vaccination dose, after the sixth vaccination and after the 
recall dose (Fig. 1). pBMCs were isolated by density-gradient 
centrifugation technique (Ficoll-Hypaque, Cederlane, 
The netherlands) and were cryopreserved until use.
T cell stimulation in vitro. Thawed PBMCs from patients 
were in vitro pre-sensitized with MUC1159-167, ErbB2368-377 
and CEA605-613 peptide-pulsed K562-A*0201 cells (kindly 
provided by Dr T. Wolfel, University of Mainz) as previously 
described (14). Briefly, K562-A*0201 cells were pulsed for 1 h 
with 10 µg/ml of peptide (Clinalfa Merck Biosciences), then 
irradiated (30 Gy, X-RayCell Irradiator) and co-coltured with 
pBMCs to the ratio 1:30 without any additional wash. Cells 
were suspended in RPMI-1640, penicillin 100 U/ml, strep-
tomycin 100 µg/ml, glutamine 2 mM (all from EuroClone), 
β-mercaptoethanol 50 mM (Sigma-Aldrich, St. Louis, MO, 
USA), 10% FCS (Biowest) [complete medium (CM)], IL-2 
10 U/ml (preproTech Inc., Rocky Hill, nJ, UsA) and rIL-15 
10 ng/ml (R&D, Minneapolis, Mn, UsA). Cytokines were 
added at day 3, 7 and 10. At day 11, cells were harvested and 
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CD8+ were purified using CD8 microbeads (MiltenyiBiotec, 
Gladbach, Germany).
Pentamer staining. Amplified CD8+ lymphocytes were 
analysed with ErbB2, MUC1 and CEA pentamers (pE) 
(proimmune, Oxford, UK) according to the manufacturer's 
instructions. Concurrently, cells were stained with anti-CD8 
pE-Cy5 (clone RpA T8) and anti-CD3 FITC (clone UCHT1) 
(both from BD Biosciences, san Diego, CA, UsA) antibodies.
ELISPOT assay. Multiscreen IpVH plates (Millipore, 
Bedford, MA, USA) were coated with 10 µg/ml of mAb 
anti-human IFNγ (BD Bioscience) in pBs w/o Ca++/Mg++ and 
plated overnight at 4˚C. After blocking, CD8+ antigen specific 
T cells (1x105/well) were plated in triplicate with irradiated 
(30 Gray) autologous pBMCs, derived from pre-vaccination 
withdrawal, pulsed with MUC1, ErbB2 or CEA peptide. Cells 
were removed 16 to 20 h later. Spots of IFNγ were detected by 
adding biotinylated anti-IFnγ antibody (5 µg/ml, 2 h at 37˚C) 
followed by AKp-streptavidin conjugate (1:1,000, 2 h at 37˚C) 
(both from BD Bioscience) and chromogen substrate (BCIp/
NBT Alkaline Phosphatase Substrate; Sigma) (50 µl/well). 
spots were counted using the Immunospot Image Analyzer 
(Aelvis, Germany). Results were evaluated by subtracting the 
median number of spots of the negative samples (unpulsed 
DCs + CD8 T cells) from median number of spots of the 
study samples (peptide pulsed DCs + CD8 T cells). In order 
to consider a sample evaluable a minimum of 20 spots above 
the background was considered. The results were analyzed as 
fold increase of the calculated values (after vaccination/before 
vaccination). Median and range values of IFNγ spots were 
calculated on the overall values of the three peptides. A 
vaccine induced CD8 T cell response was defined as at least 
2-fold increase in the IFNγ production of CD8 T cells from the 
last dose from the pre-vaccination samples.
Flow cytometry. Cell labelling was performed using the 
following monoclonal antibodies: anti-CD4 FITC (clone 
RpA T4), anti-CD45RA ApC (clone HI100), anti-CD25 pE 
(clone M-A251), and anti-FOXp3 Alexa 647 (clone 259D/C7) 
(all from BD Biosciences). For the FOXp3 intracellular staining, 
cells were permeabilized with Human Foxp3 Buffer 
(BD Biosciences). Cell phenotype was evaluated using 
FACsCanto II flow cytometer running FACsDiva data acqui-
sition and analysis software (both from Becton Dickinson).
Delayed time hypersensitivity (DTH). DTH reaction was 
used to evaluate the cellular immune response at different 
time-points of vaccination in vivo (Fig. 1). The assay was 
performed by separate intradermal injection in the region 
anti-brachioradialis of 10 µg of MUC1, ErbB2, CEA peptides 
(Clinalfa Merck Biosciences) and KLH (Intracell). positivity 
was assessed 48-72 h later and compared to the control.
Toxicity. The ECOG Common Toxicity Criteria (version, 
June 15, 2007) definition of toxicity events was applied. 
Patients were controlled, at all doses, for both local and 
systemic adverse events. By study design, progression to 
second phase occured if no significant toxicity was registered 
in the first eleven patients.
Clinical follow-up. Since the enrolment all patients were 
screened for recurrence by: physical, laboratory and imaging 
exams performed every 3 months in the absence of any new 
symptoms. Follow-up was closed after a median of 87 months, 
in July 2015.
Statistical analysis. Data were analysed using sTATA11 
(stataCorp Lp, College station, College station, TX, UsA). 
A Fisher's exact test was used to examine the significance of 
the association of the dichotomous outcomes. significance is 
indicated when the p-value is <0.05.
Results
Patients. Between 2007 and 2009, 14 patients (7 BC and 7 OC 
women) were enrolled in this trial and treated according to 
the protocol. In addition, 4 patients (1 BC and 3 OC) affected 
by recurrent/metastatic disease requested vaccination for 
compassionate use and were subjected to the same treatment. 
Immunological data from the latter patients are also described 
and used for comparison. Characteristics of all the patients are 
summarized in Table I.
Briefly, the average age of all enrolled patients was 53 
(sd, 9,9; range, 42-70 years old). BC patients were mostly 
affected by infiltrating ductal breast carcinoma. ErbB2 
Figure 1. Vaccination schedule. patient received 6 consecutive doses of vaccine every two weeks followed by a further recall dose (7th dose) at 3 months from 
the last dose. Before and after vaccination, and after the recall dose, patients were subjected to DTH.
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expression was 3+ in 57% of the patients and 2+ in 43%, 
half of the women had <3 positive lymph nodes. CEA and 
MUC1 tumour expression was respectively 71 and 100%. 
Half of the OC cases were serous adenocarcinoma at diag-
nosis, most women were affected by scarcely differentiated 
neoplasms, FIGO stage III and optimally debulked (residual 
tumour <1 cm). platinum-based adjuvant chemotherapy was 
successively administered to all OC patients. CEA, ErbB2 and 
MUC1 expression was, respectively, 43, 43 and 100%. CA-125 
levels were routinely monitored in all ovarian cancer patients 
and resulted below range of positivity also for patient OV04 
and OV011 who experienced a recurrence.
Two OC patients treated for compassionate use had been 
subjected to secondary cytoreduction and adjuvant platinum 
based second line chemotherapy. These patients were in 
clinical remission at the beginning of immunotherapy. The 
last OC patient suffered from peritoneal disease progression 
after tumour debulking and three lines of chemotherapy. The 
BC patient, treated in a compassionate setting, was a woman 
affected by pleural, brain, hepatic and bone recurrence after 
treatment with taxane, trastuzumab, lapatinib and capecitabine.
All 14 enrolled patients completed the vaccination regimen 
receiving the 6 doses of vaccine and the additional recall dose. 
Of these, 6 women received a high dose regimen. Therefore 
84 vaccinations (36 high dose) were carried out with their 
14 planned recall doses in this setting.
Three out of 4 patients undergoing vaccination for compas-
sionate use received a low dose regimen and one the high dose, 
while one out of 3 patients completed the low dose vaccination 
protocol with the recall dose. One patient completed the low 
dose vaccination protocol, but did not carry out the recall dose 
due to disease progression. One patient suspended treatment 
after the third vaccination for disease progression. One patient 
completed the high dose vaccination protocol and carried out 
the recall dose.
Evaluation of the immune response. Before vaccination, no 
enrolled patient had a specific IFnγ producing CD8+ immune 
response. At the end of the treatment, 8/14 patients showed a 
specific IFnγ producing CD8+ immune response to at least one 
antigen (Tables II and III). None of the 4 patients vaccinated 
for compassionate use showed an activation of CD8+ specific 
lymphocyte before or after vaccination (Table IV).
Among responding patients, 2/7 were BC whereas 6/7 were 
OC. Highest response rates were detected after the completion 
of the six administrations. Peptide vaccination was effective 
in inducing an immune response in 3/14, 4/10 and 4/7 for 
MUC1, ErbB2 and CEA, respectively. The low dose and high 
dose regimen induced a response in respectively 5/8 and 3/6 
patients. In Fig. 2, patient immune response to the antigenic 
peptides is presented as ratio between the IFNγ spots obtained 
after and before vaccination.
The median background of IFNγ spots of negative control 
samples (unpulsed DCs + CD8 T cells) was 23 (range, 8-178) 
before vaccination and 19 (range, 8-118) after vaccination. The 
median values of IFNγ spots of study samples (peptide pulsed 
DCs + CD8 T cells) before and after vaccination were 19 (range, 
7-296) and 42.5 (range, 8-598), respectively. Data (median and 
range) of the single peptide are summarized in Table V.
A vaccine-induced CD8 T cell response was defined as at 
least 2-fold increase in the IFNγ production of CD8 T cells from 
the last vaccination dose from the pre-vaccination samples.
Table I. Patient characteristics.
Characteristics Data
BC patient characteristics (n=7)
Median age (years) 45
Stage of tumor, n
  IA 1
  IIA 3
  IIIA 1
  IIIC 2
Histology, n
  Infiltrating ductal BC 6
  Infiltrating ductal nas BC 1
Grade, n
  I 1
  II 1
  III 5
Node status (+), n 6
Status before vaccination, n
  DF 7
OC patient characteristics (n=7)
Median age (years) 53
Stage of tumor, n
  IIA 1
  IIIA 1
  IIB 1
  IC 1
  IIIC 3
Histology, n
  Serous adenocarcinoma 4
  Endometrioid 1
  Mucinous 2
Grade, n
  II 1
  III 6
RT <1 cm, n 7
Status before vaccination, n
  DF 7
 OC (3 pzs) BC (1 pz)
Patient characteristics (compassionate use) (n=4)
Median age 60 years 40 years
Stage of tumor IIIC (2 pzs); IIB (1 pz) IV
Histology serous Infiltrating
 adenocarcinoma (3/3) ductal BC
Grade III (3/3) III
status before sD (2 pzs); pD (1 pz) pD
vaccination
DF, disease-free; sD, stable disease; pD, progression disease; RT, tumor 
residual.
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Treg trends did not appear to be correlated to a clinical 
or immunological response. Only 2/14 patients (MA07 and 
OV10) showed a decrease in circulating Tregs, one in a patient 
who showed no response to vaccination and one who showed a 
strong response to two peptides (Fig. 3).
DTH skin reactions were tested by injecting 10 µg of each 
peptide intradermal at baseline, after the sixth and after the 
seventh dose of vaccination for in vivo immunomonitoring. 
No positive reactions were detected at baseline. Five out of 14 
patients developed a positive DTH to at least one peptide after 
the recall dose.
An OC patient enrolled in the trial suffered from lymph 
nodal recurrence 14 months after primary surgery. she 
was subjected to para-aortic lymphadenectomy. she was 
then submitted to II line chemotherapy and concomitantly 
to 3 vaccination re-boosts every 3 weeks. During the first 
Table III. Ovarian cancer patients.
      Dose of      Current
 stage at Type of Type of  peptides CD8 post  DFs OS Vaccination disease status
 diagnosis surgery ADJ CHT Antigens (µg) vaccination DTH (months) (months) beginning (July 2015)
OV01 IIA primary Carboplatin +  MUC1 100 MUC1 MUC1  87 102+ Jul 2007 nED
  cytoreduction paclitaxel
   (6 cycles)
OV04 IIIC primary Carboplatin +  MUC1 100 nEG nEG   18 109+ sep 2007 pD
  cytoreduction paclitaxel
   (6 cycles)
OV05 IIIC primary Carboplatin +  MUC1 100 MUC1 nEG 128+ 133+ sep 2007 nED
  cytoreduction paclitaxel
   (6 cycles)
OV06 IC primary Carboplatin +  MUC1,  100 CEA CEA 114+ 122+ Dec 2007 nED
  cytoreduction paclitaxel  CEA
   (5 cycles)
OV07 IIIA primary Carboplatin +  MUC1,  100 ErbB2 nEG   96+ 101+ Jan 2008 nED
  cytoreduction paclitaxel  ErbB2
   (6 cycles)
OV010 IIIC primary Carboplatin +  MUC1,   500 MUC1,  nEG 104+ 111+ sep 2008 nED
  cytoreduction paclitaxel ErbB2,  ErbB2,
   (6 cycles) CEA  CEA
OV011 IIB primary Carboplatin +  MUC1,   500 ErbB2,  ErbB2   94+   99+ Jan 2009 nED
  cytoreduction paclitaxel ErbB2,  CEA
   (6 cycles) CEA
Table IV. Characteristics of patients vaccinated for compassionate use.
 stage at Clinical stage no. of  single dose CD8 CD8 post- Clinical
Patients diagnosis before vaccination vaccination Antigens peptides (ug) pre-vaccination vaccination Response
MA09 IV pD 6 MUC1-ErbB2- 500 neg neg pD
    CEA
OV02 IIIC sD 6 MUC1 100 neg neg pD
OV03 IIIC pD 3 MUC1-CEA 100 neg neg pD
OV08 IIB sD 7 MUC1 100 neg neg pD
pD, disease progression; sD, stady disease.
Table V. Median and range values of IFNγ spots produced by 
CD8 T cells before and after vaccination.
 DCs + CD8 DCs + peptide + 
 T cells CD8 T cells
 ------------------------------------------ -------------------------------------------
 Median Range Median Range
Before vaccination
CEA 22.5 8-60 40 8-80
MUC1 16 12-112 18 7-202
ErbB2 21 10-178 27.5 9-296
After vaccination
CEA 31 12-118 65 12-598
MUC1 20 8-56 15 8-160
ErbB2 39 14-100 179.5 12-390
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vaccination cycle, specific IFnγ producing CD8+ immune 
response to the ErbB2 and CEA peptides had increased 
but returned to baseline after 3 months from the treatment. 
After 5 months from the vaccination, at the time of relapse, 
specific ErbB2, CEA CD8+ circulating lymphocytes had 
increased (Fig. 4A). Interestingly CEA- and ErbB2-specific 
CD8+ lymphocytes were also identified in the removed bulky 
aortic lymph nodes (Fig. 4B). This suggests that although the 
immune response was unable to avoid recurrence, homing 
of specific lymphocytes occurred. A blood sample collected 
at 36 months from the last boost still showed specific IFnγ 
producing ErbB2 and CEA CD8+ T cells (Fig. 4C).
Toxicity. no ECOG grade 4 toxicity related to the study 
was observed. The most common adverse events were itch, 
erythema and tumescence (all maximum grade 2) in the injec-
tion site. Moreover, 6 patients referred Flu-like symptoms (all 
maximum grade 2) the day after vaccination dose. Only one 
patient developed deep venous thrombosis (grade 3) in the 
right leg that was managed with medical treatment (Table VI).
Survival. At a maximum of 8 years follow-up, all 7 BC 
patients enrolled according to protocol are alive and currently 
disease-free. One patient suffered from disease recurrence 
and was treated with surgery and adjuvant chemotherapy, she 
has been disease-free for 26 months. Out of the 7 OC patients 
enrolled, no patient has died of disease although 2 patients 
suffered from disease recurrence. These women were subjected 
to secondary cytoreduction and adjuvant chemotherapy. One of 
them is currently disease-free at the 1-year follow-up check-up 
and the other suffers from disease recurrence.
Discussion
Chemo-radio-therapy and the most recent targeted therapies 
have significantly improved the survival rates of different malig-
nancies. However, survival rates remain highly unsatisfactory 
and these standard options produce intense, debilitating and 
distressing side effects, destroying healthy tissues along with 
cancer cells. Consequently, there is a constant and clear unmet 
demand for the development of new therapeutic effective agents 
and strategies with minimal side effects.
In the present scenario, cancer immunotherapy appears to 
be a promising candidate, since clinical trials have shown posi-
tive effects on survival with minimal side effects (15,16). So far, 
different strategies of immunoactivation have been attempted 
in cancer patients, mostly adopting synergic biological mecha-
nism: peptide- or protein-based vaccinations, poxviral vectors, 
anti-idiotypic antibody-based vaccinations, dendritic cell- and 
retargeted lymphocytes. Recently, the possibilities to combine 
these strategies with unspecific unleashing T cell modulation 
and expansion have, moreover, increased interest in these 
protocols.
Among different approaches, short peptide-based vaccina-
tions have several advantages such as good immunological 
efficacy, low costs and safety. peptide tumour-associated 
antigens are usually 8-10 amino acids long with 2-3 primary 
anchor residues that interact with MHC class I-molecules 
and 2-3 residues which bind to T cell receptor (17,18). Short 
Figure 2. IFNγ production of specific CD8 T cells from vaccinated patients. 
ELISPOT analysis of IFnγ released by MUC1 (square), ErbB2 (circle) and 
CEA (pentagon) specific CD8 T lymphocytes after two weeks of amplification. 
Data are reported as fold increase obtained dividing the number of IFnγ spots 
produced before vaccination with those produced after the last dose. The values 
two fold-increased from baseline (continuous line) are considered positive.
Figure 3. Circulating Treg cell analysis in BC and OC patients. Tregs were 
analysed by cytofluorimetry for the expression of CD4, CD25 and FOXp3 
molecules. Results show CD4+CD25+FOXp3+ cells pre- and post- vaccina-
tion. Data are reported as percentage of CD4+CD25+FOXp3+ cells.
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peptides are characterized by a small size, ease of synthesis 
and manipulation, direct load on antigen presenting cells, 
and low production and administration costs (19-21). CTLs 
directed against peptides presented by MHC class I molecules 
constitute powerful effectors of the immune system against 
tumour cells.
In BC, clinical experiences with peptide-based vaccina-
tions date back to 1999 and since then ~400 women have been 
subjected to these types of vaccinations. Immunogenic epitopes 
of ErbB2 (22), MUC1 (23,24) and survivin 2B (13) have been 
adopted. Encouraging results have derived from trials espe-
cially in using ErbB2 peptide. Unfortunately, in advanced BC 
setting, immunotherapy did not show any impact on the patients' 
clinical outcome (25,26). However, promising experience in BC 
early disease setting has been gathered. Disease-free HLA-A2+ 
breast cancer patients receiving different dose regimen of 
4-6 monthly vaccinations as consolidation treatment, in fact, 
although presented with poorer prognostic factor compared to 
the control group, showed a significantly better prognosis in 
terms of both DFs and Os respect to disease-free HLA-A2- 
BC patients not subjected to vaccination program after an 
average of 2 years of follow-up. Vaccinated patients showed 
to have developed E75-specific CD8+ T cell, still detectable 
6 months after vaccination completion (27). As a consequence, 
previous experience of peptide-based vaccination in BC led 
us to understand that peptides are able to: i) induce a T CD4+ 
and T CD8+-specific immunologic response; ii) induce epitope 
spreading; iii) elicit a T cell immunity against the vaccinated 
epitope and other tumour derived proteins and iv) induce a 
subset of memory T cells.
Table VI. Vaccine toxicity.
 EOCG level of toxicity
 ----------------------------------------------------------------------------------------
  0 1 2 3 4
Leukopenia WBCx103;  18   0 0 0 0
 lymphocytes;
 granulocytes/
 bands
Thrombocytopenia plt x103 18   0 0 0 0
Anemia Hgb 18   0 0 0 0
Coagulation Fibrinogen;  18   0 0 0 0
 PT; PTT     
GU Creatinine 18   0 0 0 0
Liver Bilirubin;  18   0 0 0 0
 SGOT, SGPT     
Fever in absence  - 12   6 0 0 0
of infection
GI Nausea;  18   0 0 0 0
 vomiting; 
 diarrhea     
Skin -   0 14 4 0 0
Allergy - 17   1 0 0 0
Phlebitis - 17   0 0 1 0
Local - 16   2 0 0 0
Alopecia - 18   0 0 0 0
Figure 4. Immunomonitoring of OC patients. (A) Number of IFNγ spots released by ErbB2 (circle) and CEA (square) specific CD8 T cells at staging (01/2009), 
after the first cycle of vaccination (04/2009), at the lymph nodal recurrence (09/2009), after the para-aortic lymphadenectomy (12/2009), after the second cycle 
of vaccination (04/2010) and at follow-up (03/2013). (B) ErbB2 and CEA pentamer staining performed on purified CD8 T cells obtained from bulky aortic 
lymph node. (C) number of IFnγ spots produced by ErbB2 and CEA specific CD8 T cells purified from bulky lymph node.
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Less experience has been gathered on OC patients, 
however, the results appear to be in line with those observed 
in breast tumours. Approximately 150 women were subjected 
to peptide-based vaccination beginning in 2002 (22). Most 
immunogenic epitopes adopted in ovarian cancer setting 
were found to be mixed ErbB2 peptides and NY-ESO 
peptide (28,29). Unfortunately, most OC patients are diagnosed 
with an advanced stage and in this setting the high tumour 
burden has proved to induce systemic immunosuppression and 
subsequent immune system failure (10). As a consequence, 
the immunological exhaustion characterizing advanced OC 
patients was probably the limiting factor determining the 
absence of clinical benefit reported in the previous experience 
of immunotherapy trial in vaccinated OC patients.
In the present phase I/II study, the clinical safety and 
immune activation and modulation of consolidation therapy 
with a multipeptide vaccine were investigated in 14 BC and 
OC patients in clinical disease remission. Multipeptide vacci-
nation is safe and able to induce a specific IFnγ producing 
CD8+ immune response.
OC patients showed higher immunological responses when 
compared to BC patients. This could be partially explained by 
the platinum based regimens adopted for OC patients that have 
an indirect effect on the immune system (30). platinum-based 
therapies have in fact shown to enhance the immunostimula-
tory potential of DCs and decrease immunosuppression by 
depleting myeloid suppressor cells (31,32). CEA modified 
CAP-1 peptide appeared to be the most effective in inducing 
cellular specific immune response, whereas MUC1 peptide 
epitope, adopted in human beings for the first time, and E75 
were able to induce a specific immune response in, respectively, 
20 and 40% of patients. It is important to highlight that these 
are the first data that allow a direct comparison of the same 
vaccination schedule in two extremely different moments of 
the natural history of these neoplasms. In line with the poor 
clinical responses reported in past trials, none of the heavily 
pretreated patients or patients presenting with high tumour 
burden showed any immunological response. Although anec-
dotal, the observation is promising; it was carried out in the 
patients whose samples from recurrent disease were available. 
The high percentage of vaccine specific CD8+ lymphocytes 
in the bulky nodes demonstrates the homing phenomenon of 
newly generated immune cells. Moreover, in this patient addi-
tional recalls of the vaccine were able to re-elicit further the 
amount of specific CD8+ T cells against ErbB2 and particu-
larly to the CEA antigen that was weakly positive in the first 
vaccination.
Overall, although beyond the study objective, the clinical 
outcome of the patients enrolled in the trial appears favourable, 
having registered no patient deceased at an average 87 months 
follow-up. several enrolled patients were affected by early 
disease and therefore this may justify the survival data. The 
prolonged follow-up and the sample size are sufficient to 
exclude long-term side effects or a paradoxical detrimental 
effect on survival.
The promising results, in line with the data observed in 
similar studies, the high compliance observed by the patients 
and the favourable toxicity profile associated with minimal 
costs, support future trials of peptide vaccination in clinically 
disease-free patients who have completed standard treatments.
In conclusion, in BC and OC patients in clinical disease 
remission, multipeptide vaccination is safe and able to 
induce a specific IFnγ producing CD8+ immune response. In 
particular, OC patients appear to be more prone to activate a 
specific immune response most probably due to the synergy 
with platinum based chemotherapy.
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